New combo therapy aims to stop head and neck cancer return

NCT ID NCT00875849

Completed Disease control Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested whether adding the targeted drug cetuximab to standard chemotherapy and radiation could help prevent head and neck cancer from coming back after surgery. The study enrolled 53 patients with certain high-risk features. The main goal was to see how many patients remained cancer-free after two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cetuximab (a targeted antibody), cisplatin (chemotherapy), and radiation therapy
What this could lead to: If successful, this combination could improve the chance of keeping head and neck cancer from returning after surgery.
What could go wrong: This is a small, early-phase trial with only 53 participants. The added drugs may cause more side effects, and it's unclear if the benefits outweigh the risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms hypopharynx squamous cell carcinoma laryngeal squamous cell carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck tongue cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.